Radiopharmaceuticals Therapy and PET/SPECT Imaging – A Global Scenario (2010-2015)

Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930’s. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.

Diagnostic applications of radiopharmaceuticals have around 90% of the market share. The market is growing due to the increasing incidences of cancer and cardiac diseases, requisition of better imaging techniques for diseases such as Alzheimer’s. Targeted alpha therapy is one of the most promising treatments for cancer, which is being researched upon by cancer institutes.

Driven by the increasing incidence of cardiac and cancer diseases, early and accurate diagnosis, increasing awareness amongst the masses, and expanding application segment; the global radiopharmaceutical market reached around $3.2 billion in 2010. Radiopharmaceuticals are used for the diagnosis and treatment of various ailments such as cancer, cardiac, renal, and respiratory diseases among the others. PET machines enable radiologists in early detection of cancer, cardiac, and Alzheimer’s disease among the patients. This would increase the demand for PET machines among the healthcare centers and providers. Similarly, SPECT scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape with opportunities in the market for neuroendocrine tumor imaging. For diagnostic applications of radiopharmaceuticals, radioisotopes such as FDG for PET and technetium for SPECT are most commonly used.

PET and SPECT scans provide dynamic images of the body’s interior, rather than just the bones, like X-ray and magnetic resonance imaging (MRI). PET scan lets the doctor identify glucose metabolism in different parts of the body in a patient. Cancer cells grow at a faster rate than the other cells. The machine detects the speed of glucose being used and indicates the presence of cancerous tumors. The cancerous cell breaks down glucose at a higher rate than the other cells and this increased activity can be seen in a scan. Thus, the use of PET and SPECT scans facilitates early and accurate diagnosis of diseases such as cancer. Increased usage of PET & SPECT scans in turn increases the demand for radiopharmaceuticals.

FDG is the major radiopharmaceutical used in PET (approximately 90%). PET procedures are preferred over SPECT as PET is more accurate, sensitive, and endowed with better spatial arrangement of the image. Besides, the main radiopharmaceutical used in SPECT; i.e. technetium (99m) has a limited supply, forcing people to look for alternatives. FDG can be produced at desired levels to meet all the imaging requirements. This situation is boosting the FDG market.

Most of the radiopharmaceuticals are used in hospitals; accounting for 92%. Majority of the radiopharmaceuticals are administered intravenously. The market for radiopharmaceuticals is restricted by their high cost and difficulties faced while transporting them.

Scope of the report

This research report categorizes the radiopharmaceuticals therapy and PET/SPECT imaging market on the basis of isotopes, routes of administration, applications, and geography; forecasting revenue, and analyzing trends in each of the following submarkets:

On the basis of isotopes:

Fludeoxyglucose (F18), Technetium (Tc99m), Gallium (Ga67), Sodium Iodide (I123), Iobenguane (I131), Rhenium (Re186), Samarium (Sm153),Thallium (Tl201), Yttrium (Y90), Erbium(Er169), and others

On the basis of routes of administration:

Intravenous, peroral, inhalation, and others

On the basis of applications:

Diagnosis (PET and SPECT), indication for diagnosis, and therapy

On the basis of geography:

North America (U.S. and Canada), Europe, Asia-Pacific, Japan, and Rest of the World

Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments. In addition, the report provides more than 16 company profiles covering all the sub-segments.

TABLE OF CONTENTS 
 
EXECUTIVE SUMMARY 
  MARKET SCENARIO 
 
1 INTRODUCTION 
  1.1 KEY TAKE-AWAYS 
  1.2 REPORT DESCRIPTION 
  1.3 MARKETS COVERED 
  1.4 STAKEHOLDERS 
  1.5 RESEARCH METHODOLOGY 
 
2 SUMMARY 
 
3 MARKET OVERVIEW 
  3.1 DEFINITION OF RADIOPHARMACEUTICALS 
  3.2 EVOLUTION 
  3.3 MARKET SEGMENTATION 
  3.4 DRIVING FORCE ANALYSIS 
      3.4.1 DRIVERS 
            3.4.1.1 Increasing incidence of cancer and cardiac ailments 
            3.4.1.2 Increasing use of SPECT and PET scans 
            3.4.1.3 Rising awareness of Radiopharmaceuticals among physicians 
            3.4.1.4 Alpha radioimmunotherapy-based targeted cancer treatment 
            3.4.1.5 Ready availability of radiopharmaceuticals from cyclotrons 
      3.4.2 RESTRAINTS 
            3.4.2.1 Half-life of radiopharmaceuticals 
            3.4.2.2 High capital demand 
            3.4.2.3 Lack of good manufacturing practices (GMP) 
            3.4.2.4 Inefficient effluent treatment management 
            3.4.2.5 Stringent regulatory guidelines 
      3.4.3 THREAT 
            3.4.3.1 Shutdown of nuclear reactors impacts the production of radioisotopes 
      3.4.4 OPPORTUNITIES 
            3.4.4.1 Increasing demand for diagnosis 
            3.4.4.2 High demand in geographies with inadequate supply 
      3.5 WINNING IMPERATIVES 
      3.5.1 INTRODUCTION OF NEW AGENTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE 
      3.5.2 INCREASING REGULATORY APPROVALS OF RADIOPHARMACEUTICALS 
  3.6 BURNING ISSUES 
      3.6.1 HIGH COST OF IMAGING DEVICES 
      3.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M (RADIOISOTOPE) 
  3.7 MARKET SHARE ANALYSIS 
  3.8 END-USER ANALYSIS 
  3.9 COMPETITIVE ANALYSIS 
  3.10 PATENT ANALYSIS 
  3.11 FUTURE RADIOPHARMACEUTICALS 
 
4 RADIOPHARMACEUTICAL MARKET, BY ISOTOPES 
  4.1 INTRODUCTION 
  4.2 FLUDEOXYGLUCOSE (18F) 
      4.2.1 INCREASE IN AVAILABILITY OF HYBRID PET/CT MACHINES 
      4.2.2 RISE IN PET PROCEDURES INCREASES DEMAND FOR FDG 
      4.2.3 HIGH GENERATION COSTS OF FDG 
      4.2.4 NEED FOR SPEEDY & EFFICIENT TRANSPORTATION 
  4.3 TECHNETIUM (99MTC) 
      4.3.1 TECHNETIUM CAN COMBINE WITH 31 DIFFERENT CARRIER MOLECULES 
      4.3.2 LACK OF AVAILABILITY OF TECHNETIUM 
  4.4 THALLIUM (201TL) 
      4.4.1 THALLIUM MOST COMMON SUBSTITUTE OF TECHNETIUM 
  4.5 GALLIUM (67GA) 
  4.6 SODIUM IODIDE (123I) 
  4.7 IOBENGUANE (131I) 
  4.8 RHENIUM (186RE) 
  4.9 SAMARIUM (153SM) 
  4.10 YTTRIUM (90Y) 
  4.11 ERBIUM (169ER) 
  4.12 OTHERS 
 
5 RADIOPHARMACEUTICAL MARKET, BY ROUTES OF ADMINISTRATION (ROA) 
  5.1 INTRODUCTION 
  5.2 INTRAVENOUS ADMINISTRATION 
  5.3 INHALATION ADMINISTRATION 
  5.4 PERORAL ADMINISTRATION 
  5.5 OTHER ROUTES OF ADMINISTRATION 
 
6 RADIOPHARMACEUTICAL MARKET, BY APPLICATIONS 
  6.1 INTRODUCTION 
  6.2 RADIOPHARMACEUTICALS FOR DIAGNOSIS 
      6.2.1 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IMAGING 
            6.2.1.1 Introduction 
            6.2.1.2 Principle & procedure 
            6.2.1.3 Radiotracers 
            6.2.1.4 Limitations 
            6.2.1.5 Safety 
            6.2.1.6 Radiopharmaceuticals 
                    6.2.1.6.1 Technetium-99m 
                    6.2.1.6.2 Gallium (67Ga) 
                    6.2.1.6.3 Sodium iodide (123I) 
                    6.2.1.6.4 Iobenguane (131I) 
                    6.2.1.6.5 Rhenium (186Re) 
                    6.2.1.6.6 Thallium (201Tl) 
                    6.2.1.6.7 Yttrium (90Y) 
                    6.2.1.6.8 Others 
      6.2.2 POSITRON EMISSION TOMOGRAPHY (PET) IMAGING 
            6.2.2.1 Introduction 
            6.2.2.2 Principle & procedure 
            6.2.2.3 Radiotracers 
            6.2.2.4 Limitations 
            6.2.2.5 Safety 
            6.2.2.6 Radiopharmaceuticals 
                    6.2.2.6.1 18F-FD/Fluorodeoxyglucose (18F) 
                    6.2.2.6.2 Others 
  6.3 RADIOPHARMACEUTICAL MARKET, BY INDICATION FOR DIAGNOSIS 
      6.3.1 INTRODUCTION 
      6.3.2 CARDIAC DISEASES 
      6.3.3 NEUROIMAGING 
      6.3.4 BONE SCAN 
      6.3.5 LIVER SCAN 
      6.3.6 RESPIRATORY SCAN 
      6.3.7 RENAL SCAN 
      6.3.8 THYROID SCAN 
  6.4 RADIOPHARMACEUTICALS FOR TREATMENT/RADIONUCLIDE THERAPY (RNT) 
      6.4.1 TARGETED ALPHA THERAPY (TAT) OR ALPHA RADIOIMMUNOTHERAPY 
      6.4.2 RADIOPHARMACEUTICALS 
            6.4.2.1 Iobenguane (131I) 
            6.4.2.2 Rhenium (186Re) 
            6.4.2.3 Samarium (153Sm) 
            6.4.2.4 Erbium (Er169) 
            6.4.2.5 Others 
 
7 REGULATORY CHALLENGES FOR RADIOPHARMACEUTICALS PRODUCTION 
  7.1 INTRODUCTION 
  7.2 SAFETY OF PERSONNEL 
  7.3 EQUIPMENT & FACILITY 
  7.4 TRANSPORTATION GUIDELINES 
  7.5 GUIDELINES IN EUROPE 
  7.6 GUIDELINES IN U.S. 
  7.7 REIMBURSEMENT 
 
8 GEOGRAPHIC ANALYSIS (CONSUMPTION) 
  8.1 INTRODUCTION 
  8.2 NORTH AMERICA 
      8.2.1 U.S. 
      8.2.2 CANADA 
  8.3 EUROPE 
  8.4 APAC (EXCLUDING JAPAN) 
  8.5 JAPAN 
  8.6 REST OF THE WORLD (ROW) 
 
9 GEOGRAPHIC ANALYSIS (PRODUCTION) 
  9.1 INTRODUCTION 
  9.2 NORTH AMERICA 
  9.3 EUROPE 
  9.4 APAC (EXCLUDING JAPAN) 
  9.5 JAPAN 
  9.6 REST OF THE WORLD 
 
10 COMPETITIVE LANDSCAPE 
 
11 COMPANY PROFILES 
  11.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 
      11.1.1 OVERVIEW 
      11.1.2 PRODUCTS & SERVICES 
      11.1.3 FINANCIALS 
      11.1.4 STRATEGY 
      11.1.5 DEVELOPMENTS 
  11.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 
      11.2.1 OVERVIEW 
      11.2.2 PRODUCTS & SERVICES 
  11.3 CARDINAL HEALTH INC 
      11.3.1 OVERVIEW 
      11.3.2 PRODUCTS & SERVICES 
      11.3.3 FINANCIALS 
      11.3.4 STRATEGY 
      11.3.5 DEVELOPMENTS 
  11.4 COVIDIEN PLC 
      11.4.1 OVERVIEW 
      11.4.2 PRODUCTS & SERVICES 
      11.4.3 FINANCIALS 
      11.4.4 STRATEGY 
      11.4.5 DEVELOPMENTS 
  11.5 ECZACIBASI-MONROL 
      11.5.1 OVERVIEW 
      11.5.2 PRODUCTS & SERVICES 
      11.5.3 STRATEGY 
      11.5.4 FINANCIALS 
      11.5.5 DEVELOPMENTS 
  11.6 FUJIFILM HOLDINGS CORP 
      11.6.1 OVERVIEW 
      11.6.2 PRODUCTS & SERVICES 
      11.6.3 FINANCIALS 
      11.6.4 STRATEGY 
      11.6.5 DEVELOPMENTS 
  11.7 GE HEALTHCARE 
      11.7.1 OVERVIEW 
      11.7.2 PRODUCTS & SERVICES 
      11.7.3 FINANCIALS 
      11.7.4 STRATEGY 
      11.7.5 DEVELOPMENTS 
  11.8 IBA GROUP 
      11.8.1 OVERVIEW 
      11.8.2 PRODUCTS & SERVICES 
      11.8.3 FINANCIALS 
      11.8.4 STRATEGY 
      11.8.5 DEVELOPMENTS 
  11.9 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE (POLATOM) 
      11.9.1 OVERVIEW 
      11.9.2 PRODUCTS & SERVICES 
      11.9.3 STRATEGY 
      11.9.4 DEVELOPMENTS 
  11.10 INSTITUTE OF ISOTOPES CO. LTD. 
      11.10.1 OVERVIEW 
      11.10.2 PRODUCTS & SERVICES 
      11.10.3 STRATEGY 
  11.11 INSTITUTE OF RADIOELEMENT (IRE) 
      11.11.1 OVERVIEW 
      11.11.2 PRODUCTS & SERVICES 
      11.11.3 STRATEGY 
      11.11.4 DEVELOPMENTS 
  11.12 LANTHEUS MEDICAL IMAGING INC 
      11.12.1 OVERVIEW 
      11.12.2 PRODUCTS & SERVICES 
      11.12.3 FINANCIALS 
      11.12.4 STRATEGY 
      11.12.5 DEVELOPMENTS 
  11.13 NORDION INC. 
      11.13.1 OVERVIEW 
      11.13.2 PRODUCTS & SERVICES 
      11.13.3 FINANCIALS 
      11.13.4 STRATEGY 
      11.13.5 DEVELOPMENTS 
  11.14 NTP RADIOISOTOPES (PTY) LTD 
      11.14.1 OVERVIEW 
      11.14.2 PRODUCTS & SERVICES 
      11.14.3 FINANCIALS 
      11.14.4 STRATEGY 
      11.14.5 DEVELOPMENTS 
  11.15 SAMYOUNG UNITECH CO. LTD 
      11.15.1 OVERVIEW 
      11.15.2 PRODUCTS & SERVICES 
      11.15.3 FINANCIALS 
      11.15.4 STRATEGY 
  11.16 SIEMENS HEALTHCARE 
      11.16.1 OVERVIEW 
      11.16.2 PRODUCTS & SERVICES 
      11.16.3 FINANCIALS 
      11.16.4 STRATEGY 
      11.16.5 DEVELOPMENTS 
 
APPENDIX 
  U.S. PATENTS 
  EUROPE PATENTS 
  JAPAN PATENTS 
  WIPO PATENTS  
    
 
LIST OF TABLES 
 
TABLE 1  GLOBAL RADIOPHARMACEUTICAL MARKET REVENUE, BY APPLICATIONS, 2008 – 2015 ($MILLION) 
TABLE 2  RADIOPHARMACEUTICAL MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 3  RADIOPHARMACEUTICALS IN CLINICAL TRIALS
TABLE 4  RADIOPHARMACEUTICALS SEGMENTATION
TABLE 5  GLOBAL RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 – 2015 ($THOUSAND) 
TABLE 6  RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 7  NORTH AMERICA: RADIOPHARMACEUTICAL MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 8  FDG MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND)
TABLE 9  NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 10 INDICATIONS DIAGNOSED BY TECHNETIUM 
TABLE 11 TECHNETIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 12 NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 13 THALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 14 NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 15 GALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 16 NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 17 SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 18 NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 19 IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 20 NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 21 RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 22 NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 23 SAMARIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 24 NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 25 YTTRIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 26 NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 27 ERBIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 28 NORTH AMERICA: ERBIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 29 OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 30 NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 31 GLOBAL RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY TYPES, 2008 – 2015 ($MILLION) 
TABLE 32 RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 33 NORTH AMERICA: RADIOPHARMACEUTICALS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 34 INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 35 NORTH AMERICA: INTRAVENOUS ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 36 INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 37 NORTH AMERICA: INHALATION ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 38 PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 39 NORTH AMERICA: PERORAL ROUTE OF ADMINISTRATION MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 40 OTHER TYPES OF ROUTES OF ADMINISTRATION 
TABLE 41 OTHER ROUTES OF ADMINISTRATION MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 42 NORTH AMERICA: OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 43 GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 – 2015 ($MILLION) 
TABLE 44 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 45 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 46 GLOBAL SPECT RADIOPHARMACEUTICALS MARKET, BY TYPES, 2008 – 2015 ($THOUSAND) 
TABLE 47 SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 48 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 49 TECHNETIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 50 NORTH AMERICA: TECHNETIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 51 GALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 52 NORTH AMERICA: GALLIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 53 SODIUM IODIDE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 54 NORTH AMERICA: SODIUM IODIDE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 55 IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 56 NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 57 RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 58 NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 59 THALLIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 60 NORTH AMERICA: THALLIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 61 YTTRIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 62 NORTH AMERICA: YTTRIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 63 OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 64 NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 65 GLOBAL PET RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 – 2015 ($MILLION) 
TABLE 66 PET RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION) 
TABLE 67 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRIES, 2008 – 2015 ($MILLION) 
TABLE 68 FDG MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 69 NORTH AMERICA: FDG MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 70 OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 71 NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 72 TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY TYPES, 2008 – 2015 ($THOUSAND) 
TABLE 73 TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 74 NORTH AMERICA: TREATMENT RADIOPHARMACEUTICALS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 75 IOBENGUANE MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 76 NORTH AMERICA: IOBENGUANE MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 77 RHENIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 78 NORTH AMERICA: RHENIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 79 SAMARIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 80 NORTH AMERICA: SAMARIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 81 ERBIUM MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 82 NORTH AMERICA ERBIUM MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 83 OTHER RADIOPHARMACEUTICALS, BY TYPES 
TABLE 84 OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($THOUSAND) 
TABLE 85 NORTH AMERICA: OTHERS MARKET REVENUE, BY COUNTRIES, 2008 – 2015 ($THOUSAND) 
TABLE 86 NORTH AMERICA: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 87 U.S: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 88 CANADA: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 89 EUROPE: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 90 APAC: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 91 JAPAN: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 92 ROW: RADIOPHARMACEUTICALS MARKET REVENUE, BY RADIOISOTOPES, 2008 – 2015 ($THOUSAND) 
TABLE 93 MERGERS & ACQUISITIONS 
TABLE 94 AGREEMENTS & COLLABORATIONS 
TABLE 95 NEW PRODUCT DEVELOPMENT 
TABLE 96 NEW EXPANSION FACILITIES 
TABLE 97 APPROVALS 
TABLE 98 ANSTO HEALTH: MARKET REVENUE, 2008 – 2010 ($MILLION) 
TABLE 99 CARDINAL: MARKET REVENUE, 2008 – 2010 ($MILLION) 
TABLE 100 CARDINAL: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 101 COVIDIEN: MARKET SALES AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 102 COVIDIEN: MARKET SALES, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 103 COVIDIEN: MARKET REVENUE, BY SEGMENT, 2008 – 2010 ($MILLION) 
TABLE 104 COVIDIEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 105 FUJIFILM: MARKET REVENUE, 2009 – 2011 ($MILLION) 
TABLE 106 FUJIFILM: MARKET REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 107 FUJIFILM: MEDICAL SYSTEM SEGMENT REVENUE, 2009 – 2011 ($MILLION) 
TABLE 108 FUJIFILM: MARKET REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 109 GE HEALTHCARE: MARKET REVENUE AND R&D EXPENSES, 2007 – 2009 ($BILLION) 
TABLE 110 GE HEALTHCARE: MARKET REVENUE, BY SEGMENT, 2007 – 2009 ($BILLION) 
TABLE 111 GE HEALTHCARE: MARKET REVENUE, BY GEOGRAPHY, 2007 – 2009 ($BILLION) 
TABLE 112 IBA GROUP: TOTAL MARKET REVENUE, 2008 – 2010 ($MILLION) 
TABLE 113 IBA GROUP: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 114 IBA GROUP: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 115 LANTHEUS: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($THOUSAND) 
TABLE 116 LANTHEUS: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($THOUSAND) 
TABLE 117 LANTHEUS: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010 ($THOUSAND) 
TABLE 118 NORDION: MARKET REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 119 NORDION: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 120 NORDION: MARKET REVENUE, BY COUNTRIES, 2008 – 2010 ($MILLION) 
TABLE 121 SIEMENS HEALTHCARE: TOTAL MARKET REVENUE, 2008 – 2010 ($MILLION) 
TABLE 122 SIEMENS HEALTHCARE: MARKET REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
 
  
LIST OF FIGURES  
 
FIGURE 1 RADIOPHARMACEUTICAL MARKET, BY RADIOISOTOPES, 2008 – 2015 
FIGURE 2 EVOLUTION IN RADIOPHARMACEUTICALS 
FIGURE 3 RADIOPHARMACEUTICALS: MARKET SEGMENTATION 
FIGURE 4 FACTORS DRIVING THE RADIOPHARMACEUTICALS MARKET 
FIGURE 5 RADIOPHARMACEUTICAL MARKET SHARE ANALYSIS, 2010 
FIGURE 6 ANALYSIS OF RADIOPHARMACEUTICALS MARKET, BY END-USERS, 2010 
FIGURE 7 COMPETITIVE LANDSCAPE FOR RADIOPHARMACEUTICALS MARKET 
FIGURE 8 PATENT ANALYSIS, BY ASSIGNEE, 2005 – 2010 
FIGURE 9 GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY PRODUCTION 
FIGURE 10 GLOBAL RADIOPHARMACEUTICALS MARKET: COMPETITIVE LANDSCAPE

Radiopharmaceuticals Therapy and PET/SPECT Imaging Market to reach $4,734 Million by 2015

Radiopharmaceuticals are medical formulations containing radioisotopes and are safe for humans in diagnosis and therapy. Radioisotopes contribute in several sectors of the economy such as food processing, medicine, agriculture, and research. Radioisotopes, in medicine, are used either in liquid form (radiopharmaceuticals) or solid form (sealed source).

Radiopharmaceuticals are defined as the pharmaceuticals that incorporate one or more radioactive isotopes. These are majorly used for diagnostic purposes. Technetium for single photon emission computed tomography (SPECT) and fludeoxyglucose (FDG) for positron emission tomography (PET) are the common radiopharmaceuticals used for diagnosis of various diseases.

Cancer and cardiac mortality have been on the rise. Globally, around 12 million deaths are expected due to cancer by 2030, and approximately 17 million people die due to cardiac diseases every year. Early detection and treatment of cancer can prevent around one-third of the cancer related deaths. In the U.S. alone, around 1.5 million new cases of cancer were reported in 2010. Radiopharmaceuticals such as FDG, samarium, technetium, and others are used in the imaging technologies for the diagnosis of cancer and cardiac diseases. Radiopharmaceuticals help in early and accurate detections of diseases. However, with the increasing incidence of cancer; demand for radiopharmaceuticals used for diagnosis and treatment would also increase.

FACTORS DRIVING THE RADIOPHARMACEUTICALS MARKET


Source: MarketsandMarkets analysis